Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Daniel R Malan"'
Autor:
Jayesh Desai, Stephane Dalle, Jermaine Coward, Daniel Brungs, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Piotr Koralewski, Iwona Lugowska, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan, Rahul Ladwa, Eva Muñoz-Couselo, Henri Montaudié, Miguel-Ángel Berciano-Guerrero, Dean Laurence Harris, Susan Arnold, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Vinay Sharma, Hong Shue, Chaiyut Charoentum, Oleksandr Dudnichenko
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients ex
Externí odkaz:
https://doaj.org/article/ba79bd85b8124e27b03c0ee657e71ed1
Autor:
Johnny N. Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R. Malan, Silva Zupančić Šalek, Michael Wang, Lisa N. Boggio, Inga Hegemann, Andrzej Mital, Matthew Cardinal, Tong Zhu, Pengling Sun, Steven Arkin
Publikováno v:
British Journal of Haematology. 200:229-239
A phase 1b/2, three-month study of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), was conducted in participants with haemophilia A or B, with or without inhibitors. Participants assigned to four cohorts rec
Autor:
Johnny Mahlangu, Jose Luis Lamas, Juan Cristobal Morales, Daniel R. Malan, John Teeter, Robert J. Charnigo, Eunhee Hwang, Steven Arkin
Publikováno v:
British journal of haematologyREFERENCES.
Marstacimab, an investigational human monoclonal antibody targeting tissue factor pathway inhibitor, demonstrated safety and efficacy in preventing bleeding episodes in patients with haemophilia. This multicentre, open-label study investigated safety